These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 28487565)
1. Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study. Oda K; Kotani T; Takeuchi T; Ishida T; Shoda T; Isoda K; Yoshida S; Nishimura Y; Makino S Sci Rep; 2017 May; 7(1):1635. PubMed ID: 28487565 [TBL] [Abstract][Full Text] [Related]
2. Increased Serum LIGHT Levels Correlate with Disease Progression and Severity of Interstitial Pneumonia in Patients with Dermatomyositis: A Case Control Study. Kotani T; Takeuchi T; Ishida T; Masutani R; Isoda K; Hata K; Yoshida S; Makino S; Hanafusa T PLoS One; 2015; 10(10):e0140117. PubMed ID: 26448572 [TBL] [Abstract][Full Text] [Related]
3. Correlation of increased serum leucine-rich α2-glycoprotein levels with disease prognosis, progression, and activity of interstitial pneumonia in patients with dermatomyositis: A retrospective study. Ishida T; Kotani T; Serada S; Fujimoto M; Takeuchi T; Makino S; Naka T PLoS One; 2020; 15(6):e0234090. PubMed ID: 32479560 [TBL] [Abstract][Full Text] [Related]
4. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis. Arai S; Kurasawa K; Maezawa R; Owada T; Okada H; Fukuda T Mod Rheumatol; 2013 Sep; 23(5):872-83. PubMed ID: 22983659 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Fujiki Y; Kotani T; Isoda K; Ishida T; Shoda T; Yoshida S; Takeuchi T; Makino S Mod Rheumatol; 2018 Jan; 28(1):133-140. PubMed ID: 28490218 [TBL] [Abstract][Full Text] [Related]
6. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis. Chen M; Quan C; Diao L; Xue F; Xue K; Wang B; Li X; Zhu X; Zheng J; Cao H Br J Dermatol; 2018 Dec; 179(6):1334-1341. PubMed ID: 30101523 [TBL] [Abstract][Full Text] [Related]
7. Pre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute/subacute interstitial pneumonia in dermatomyositis treated by cyclosporine a/glucocorticosteroid combination therapy: a case control study [corrected]. Isoda K; Takeuchi T; Kotani T; Hata K; Shoda T; Ishida T; Yoshida S; Kimura Y; Makino S; Hanafusa T PLoS One; 2014; 9(2):e89610. PubMed ID: 24586910 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Bilgic H; Ytterberg SR; Amin S; McNallan KT; Wilson JC; Koeuth T; Ellingson S; Newman B; Bauer JW; Peterson EJ; Baechler EC; Reed AM Arthritis Rheum; 2009 Nov; 60(11):3436-46. PubMed ID: 19877033 [TBL] [Abstract][Full Text] [Related]
9. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008 [TBL] [Abstract][Full Text] [Related]
10. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783 [TBL] [Abstract][Full Text] [Related]
11. Multivariate logistic regression analysis of poor prognosis of dermatomyositis and clinical value of ferritin/Kl-6 in predicting prognosis. Yan L; Shi Y; Wu C; Li Y Skin Res Technol; 2024 May; 30(5):e13701. PubMed ID: 38682785 [TBL] [Abstract][Full Text] [Related]
12. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody. Isoda K; Kotani T; Takeuchi T; Kiboshi T; Hata K; Ishida T; Otani K; Kamimori T; Fujiwara H; Shoda T; Makino S Rheumatol Int; 2017 Aug; 37(8):1335-1340. PubMed ID: 28451794 [TBL] [Abstract][Full Text] [Related]
13. HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease. Shu X; Peng Q; Lu X; Wang G PLoS One; 2016; 11(8):e0161436. PubMed ID: 27537498 [TBL] [Abstract][Full Text] [Related]
14. Serum TARC/CCL17 levels are increased in dermatomyositis associated with interstitial lung disease. Kawashima T; Tada Y; Asano Y; Yazawa N; Tomita M; Tamaki Z; Kubo M; Ihn H; Sugaya M; Kadono T; Tamaki K; Sato S J Dermatol Sci; 2010 Oct; 60(1):52-4. PubMed ID: 20800454 [No Abstract] [Full Text] [Related]
15. HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients. Zou J; Guo Q; Chi J; Wu H; Bao C Clin Rheumatol; 2015 Apr; 34(4):707-14. PubMed ID: 25609178 [TBL] [Abstract][Full Text] [Related]
16. Potential of Krebs von den Lungen-6 as a predictor of relapse in interstitial pneumonia with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis. Isoda K; Kotani T; Takeuchi T; Konma J; Ishida T; Hata K; Otani K; Fujiwara H; Shoda T; Makino S; Arawaka S Clin Respir J; 2018 Jul; 12(7):2235-2241. PubMed ID: 29633527 [TBL] [Abstract][Full Text] [Related]
17. Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease. Zou J; Chen J; Yan Q; Guo Q; Bao C Clin Rheumatol; 2016 Jan; 35(1):117-25. PubMed ID: 26459323 [TBL] [Abstract][Full Text] [Related]
18. Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. Antonelli A; Fallahi P; Ferrari SM; Corrado A; Sebastiani M; Giuggioli D; Miccoli M; Zignego AL; Sansonno D; Marchi S; Ferri C Clin Rheumatol; 2013 Aug; 32(8):1147-54. PubMed ID: 23559389 [TBL] [Abstract][Full Text] [Related]
19. KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker. Hanaoka M; Katsumata Y; Kawasumi H; Kawaguchi Y; Yamanaka H Mod Rheumatol; 2019 Jul; 29(4):625-632. PubMed ID: 30484723 [No Abstract] [Full Text] [Related]
20. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis. Peng QL; Zhang YM; Liang L; Liu X; Ye LF; Yang HB; Zhang L; Shu XM; Lu X; Wang GC Clin Exp Immunol; 2020 Mar; 199(3):314-325. PubMed ID: 31797350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]